Anti-Tcl1 antibody [1-21]

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.

Activity summary

The TCL1 (T-cell leukemia/lymphoma protein 1) also known as TCL1A is an important protein involved in cellular processes. TCL1 has a molecular mass of approximately 14 kDa and plays roles in signal transduction pathways. The protein is expressed in various tissues including the thymus lymph nodes and spleen. TCL1 is particularly important in T-cell development and function. It functions at a mechanistic level by interacting with other proteins thereby influencing cell signaling pathways essential for lymphocyte proliferation and survival.

Biological function summary

TCL1 enhances the activity of the AKT kinase an important component of cellular signaling that modulates cell growth and survival. This protein does not form any large complex but acts through AKT phosphorylation. The activation of TCL1 leads to the promotion of cell proliferation and prevention of apoptosis especially in lymphocytes. The regulation of these cellular activities by TCL1 suggests its important role in the development of the immune system.

Pathways

The AKT signaling pathway is significantly influenced by TCL1 controlling cell growth division and apoptosis. The interaction of TCL1 with AKT activates the PI3K/AKT pathway an important signal transduction pathway promoting survival and growth in response to extracellular signals. TCL1 indirectly affects the mTOR signaling pathway through its modulation of AKT affecting protein synthesis and cell metabolism. Both pathways emphasize the broad role of TCL1 in maintaining normal cellular functions and growth regulation.

Associated diseases and disorders

The overexpression or mutation of TCL1 can lead to malignancies such as T-cell leukemia and B-cell lymphoma. In these cancers abnormal TCL1 activity results in enhanced cell survival and proliferation contributing to tumorigenesis. In leukemia TCL1 directly interacts with AKT and its dysregulation becomes pathogenic. Research continues to investigate the involvement of TCL1 in oncogenesis and how its association with AKT and other signaling molecules like mTOR contributes to cancer progression. Understanding these interactions could potentially offer new therapeutic targets for treating related malignancies.